乌金祛湿酒治疗类风湿关节炎的临床观察

Abstract
Figure/Table
References (24)
Related Citation (15)

Download: PDF (711 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the clinical effect of Wujin Qushi Decoction on patients with rheumatoid arthritis (RA). Methods A total of 87 patients with RA admitted to Beijing Geriatric Hospital from March 2014 to March 2015 met the inclusion criteria were selected. They were divided into the observation group (44 cases) and the control group (43 cases) randomly according to the random number table method. The observation group was given Wujin Qushi Decoction once a day in the morning and once in the evening, each time taking 10 mL orally. And the control group was given Methotrexate 10 mg once a week. Both groups had treatment for 8 weeks. During the treatment, VAS score, number of joint pain, swollen joint count, morning stiffness duration, adverse reactions, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF) and the use of non-steroidal anti-inflammatory drug (NSAIDs) were measured. Results After the treatment, the control rate of the observation group was higher than that of the control group, the difference was statistically significant (all P ＜ 0.05). Compared with before treatment, VAS score, number of joint pain, swollen joint count, morning stiffness duration, ESR, CRP, RF and other laboratory indicators in the two groups were all reduced after treatment (P ＜ 0.05), and the observation group was lower than control group (P ＜ 0.05). The use rate of non-steroidal anti-inflammatory drugs and incidence of adverse reactions in the observation group were lower than those in the control group, and the differences were statistically significant (P ＜ 0.05). Conclusion Wujin Qushi Decoction is effective in the treatment of rheumatoid arthritis, and has more advantages than Methotrexate in relieving clinical symptoms and signs, and the adverse reactions are less than Methotrexate.

Key words： Rheumatoid arthritis Wujin Qushi Decoction Methotrexate Random-controlled trial

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Juanhong1 LIU Hongfu1 LI Guiying2

Cite this article:

LI Juanhong1 LIU Hongfu1 LI Guiying2. Clinical observation on treatment of rheumatoid arthritis with Wujin Qushi Decoction[J]. 中国医药导报, 2019, 16(31): 131-134.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I31/131

[1] 中华医学会风湿病学分会.类风湿关节炎诊断及治疗指南[J].中华风湿病学杂志，2010，14（4）：265-270.
[2] Smolen JS，Langewe R，Bijlsma J，et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs：2016 update [J]. Aun Rheum Dis，2017，76（6）：960-977.
[3] De Hair MJH，Jacobs JWG，Schoneveld JLM，et al. Difficult-to-treat rheumatoid arthritis：an area of unment clinical need [J]. Rheumatology，2017，57（7）：1135-1144.
[4] 杜尧，李晓声，曾文魁.类风湿性关节炎治疗进展[J].中国实用医药，2010，5（2）：237-238.
[5] Woodworth TG，den Broeder AA. Treating to target in established rheumatoid arthritis：Challenges and opportunities in an era of novel targeted therapies and biosimilars [J]. Best Pract Res Clin Rheumatol，2015，29（4）：543-549.
[6] 李世梅，王黎明，陈继正，等.鹿瓜多肽、丹参酮ⅡA 联合DMAＲDs 治疗类风湿性关节炎疗效观察[J].陕西医学杂志，2015，44（6）：744-746.
[7] 吕媛，陈向红，黄闰月，等.化瘀强肾通痹方联合MTX治疗类风湿关节炎的临床观察[J].中国中西医结合杂志，2019（4）：1-6.
[8] 吕芳，李兴福.2010年美国风湿病学会联合欧洲抗风湿病联盟的类风湿关节炎分类标准解读[J].诊断学理论与实践，2010，9（4）：307-310.
[9] 国家中医药管理局.中医病证诊断疗效标准[M].南京：南京大学出版社，1994：30.
[10] 郑筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社，2002：156.
[11] 刘维.中西医结合风湿免疫病学[M].武汉：华中科技大学出版社，2009：185-199.
[12] 马欣蕾，照日格图.中西医关于类风湿关节炎发病机制研究新进展[J].新疆中医药，19，37（1）：117-120.
[13] 温博，曾升平.类风湿关节炎的研究进展[J].世界中西医结合杂志，2014，9（9）：1014-1019.
[14] Geng Y，Han J，Deng X，et al. Deep linical remission：an optimized target in the management of rheumatoid arthritis? Experience from an ultra-sonography study [J]. Clin Rheumatol，16，34（4）：581-586.
[15] 磨红，马宗伯，吴成龙.类风湿关节炎治疗研究进展[J].内科，2017，2（3）：334-336.
[16] Ajeganova S，van Steenbergen HW，van Nies JA，et al. Disease-modifying antirheumatic drugs-free sustained remission in rbeumatoid arthritis：an increasingly achievable outcome with subsidence of disease symptoms [J]. Ann Rheum Dis，2016，5（5）：867-873.
[17] 马万明，岳飞利，白珊珊，等.类风湿性关节炎患者外周血白细胞介素-37及可溶性PD-1分子的检测价值分析[J].成都医学院学报，2017，12（4）：488-491.
[18] 赵宝利，黄可儿，赵敏.类风湿关节炎中医辨证分型的判别分析[J].中华中医药杂志：原中国医药学报，2012， 27（1）：240-242.
[19] 侯雷，马武开.类风湿关节炎中医证候分类临床文献研究[J].中国中西医结合杂志，2014，34（3）：279-283.
[20] 陈红梅.MTX、柳氮磺吡啶、硫酸羟氯喹联合治疗老年类风湿关节炎患者的疗效及对血脂的影响[J].中国老年学杂志，2015，21（5）：1254-1256.
[21] 达明莲，邓肇达，鲁锦玥，等.甲氨蝶呤与Th17/Treg细胞平衡对类风湿关节炎的作用机制研究[J].医学综述，2017，23（15）：3046-3050.
[22] 陈朝蔚，孙剑，李玉梅.沈氏羌活地黄汤治疗类风湿关节炎随机对照临床试验[J].中西医结合学报，2010，8（1）：35-39.
[23] 董卫芹，沈洁，吴英，等.骨瓜提取物对活动期类风湿性关节炎的疗效和安全性临床分析[J].中国现代医生，2017， 55（2）：23-26.
[24] 沈丕安.中药药理与临床运用[M].北京：人民卫生出版社，2006：101.